These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 12030837)

  • 21. Modulation of peroxisome proliferator-activated receptor delta activity affects neural cell adhesion molecule and polysialyltransferase ST8SiaIV induction by teratogenic valproic acid analogs in F9 cell differentiation.
    Lampen A; Grimaldi PA; Nau H
    Mol Pharmacol; 2005 Jul; 68(1):193-203. PubMed ID: 15829700
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relative developmental toxicity of glycol ether alkoxy acid metabolites in the embryonic stem cell test as compared with the in vivo potency of their parent compounds.
    de Jong E; Louisse J; Verwei M; Blaauboer BJ; van de Sandt JJ; Woutersen RA; Rietjens IM; Piersma AH
    Toxicol Sci; 2009 Jul; 110(1):117-24. PubMed ID: 19401353
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prediction of in vivo embryotoxic effect levels with a combination of in vitro studies and PBPK modelling.
    Verwei M; van Burgsteden JA; Krul CA; van de Sandt JJ; Freidig AP
    Toxicol Lett; 2006 Aug; 165(1):79-87. PubMed ID: 16517103
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Axial skeletal and Hox expression domain alterations induced by retinoic acid, valproic acid, and bromoxynil during murine development.
    Kawanishi CY; Hartig P; Bobseine KL; Schmid J; Cardon M; Massenburg G; Chernoff N
    J Biochem Mol Toxicol; 2003; 17(6):346-56. PubMed ID: 14708090
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of medicinal compounds on the differentiation of the eukaryotic microorganism dictyostelium discoideum: can this model be used as a screening test for reproductive toxicity in humans?
    Dannat K; Tillner J; Winckler T; Weiss M; Eger K; Dingermann T
    Pharmazie; 2003 Mar; 58(3):204-10. PubMed ID: 12685815
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction of teratogenic potency of valproate analogues using cerebellar aggregation cultures.
    Maar TE; Ellerbeck U; Bock E; Nau H; Schousboe A; Berezin V
    Toxicology; 1997 Jan; 116(1-3):159-68. PubMed ID: 9020517
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NTP technical report on the toxicity studies of Dibutyl Phthalate (CAS No. 84-74-2) Administered in Feed to F344/N Rats and B6C3F1 Mice.
    Marsman D
    Toxic Rep Ser; 1995 Apr; 30():1-G5. PubMed ID: 12209194
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Establishment of a molecular embryonic stem cell developmental toxicity assay.
    Panzica-Kelly JM; Brannen KC; Ma Y; Zhang CX; Flint OP; Lehman-McKeeman LD; Augustine-Rauch KA
    Toxicol Sci; 2013 Feb; 131(2):447-57. PubMed ID: 23042729
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Struggles for equivalence: in vitro developmental toxicity model evolution in pharmaceuticals in 2006.
    Chapin R; Stedman D; Paquette J; Streck R; Kumpf S; Deng S
    Toxicol In Vitro; 2007 Dec; 21(8):1545-51. PubMed ID: 17137747
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Developmentally regulated promoters from Dictyostelium discoideum as molecular markers for testing potential teratogens.
    Tillner J; Winckler T; Dingermann T
    Pharmazie; 1996 Nov; 51(11):902-6. PubMed ID: 8985980
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative molecular pathology of cadmium- and all-trans-retinoic acid-induced postaxial forelimb ectrodactyly.
    Liao X; Lee GS; Shimizu H; Collins MD
    Toxicol Appl Pharmacol; 2007 Nov; 225(1):47-60. PubMed ID: 17884124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessing the potential of fish cell lines as tools for the cytotoxicity testing of estuarine sediment aqueous elutriates.
    Davoren M; Ní Shúilleabháin S; Hartl MG; Sheehan D; O'Brien NM; O'Halloran J; Van Pelt FN; Mothersill C
    Toxicol In Vitro; 2005 Apr; 19(3):421-31. PubMed ID: 15713549
    [TBL] [Abstract][Full Text] [Related]  

  • 34. S-2-pentyl-4-pentynoic hydroxamic acid and its metabolite s-2-pentyl-4-pentynoic acid in the NMRI-exencephaly-mouse model: pharmacokinetic profiles, teratogenic effects, and histone deacetylase inhibition abilities of further valproic acid hydroxamates and amides.
    Eikel D; Hoffmann K; Zoll K; Lampen A; Nau H
    Drug Metab Dispos; 2006 Apr; 34(4):612-20. PubMed ID: 16415118
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative teratological investigation of compounds structurally and pharmacologically related to thalidomide.
    Helm FC; Frankus E; Friderichs E; Graudums I; Flohé L
    Arzneimittelforschung; 1981; 31(6):941-9. PubMed ID: 7196239
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alternative experimental approaches for interpreting skeletal findings in safety studies.
    Augustine-Rauch K
    Birth Defects Res B Dev Reprod Toxicol; 2007 Dec; 80(6):497-504. PubMed ID: 18157901
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of drug induced developmental toxicity using human embryonic stem cells.
    Mehta A; Konala VB; Khanna A; Majumdar AS
    Cell Biol Int; 2008 Nov; 32(11):1412-24. PubMed ID: 18778783
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Critical period for a teratogenic VLA-4 antagonist: Developmental effects and comparison of embryo drug concentrations of teratogenic and non-teratogenic VLA-4 antagonists.
    Crofts F; Rohatagi S; Pino M; DeLise B; Zhang J; Nguyen M; Guittin P; Barbellion S; Brunel P; Hofmann T; Schmidt J; Wong M; Lockey P; Lerman S; Clark R
    Birth Defects Res B Dev Reprod Toxicol; 2004 Apr; 71(2):69-79. PubMed ID: 15098200
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo.
    Shabbeer S; Kortenhorst MS; Kachhap S; Galloway N; Rodriguez R; Carducci MA
    Prostate; 2007 Jul; 67(10):1099-110. PubMed ID: 17477369
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Myo-inositol enhances teratogenicity of valproic acid in the mouse.
    Massa V; Wlodarczyk B; Giavini E; Finnell RH
    Birth Defects Res A Clin Mol Teratol; 2006 Mar; 76(3):200-4. PubMed ID: 16511884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.